XY Capital Ltd acquired a new position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 305,397 shares of the company's stock, valued at approximately $11,037,000. Zai Lab accounts for 3.2% of XY Capital Ltd's holdings, making the stock its 6th largest holding. XY Capital Ltd owned 0.28% of Zai Lab at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in ZLAB. GF Fund Management CO. LTD. bought a new stake in Zai Lab in the 4th quarter worth approximately $29,000. Pictet Asset Management Holding SA bought a new position in Zai Lab in the 4th quarter worth $31,000. Advisors Preferred LLC bought a new position in shares of Zai Lab during the 1st quarter valued at about $110,000. Barclays PLC boosted its holdings in shares of Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock valued at $97,000 after purchasing an additional 2,856 shares during the last quarter. Finally, Palumbo Wealth Management LLC bought a new position in shares of Zai Lab during the 1st quarter valued at about $203,000. 41.65% of the stock is currently owned by hedge funds and other institutional investors.
Zai Lab Price Performance
NASDAQ ZLAB traded down $0.45 during trading hours on Tuesday, hitting $34.21. 181,612 shares of the company's stock traded hands, compared to its average volume of 994,491. Zai Lab Limited Unsponsored ADR has a 52-week low of $16.01 and a 52-week high of $44.34. The company has a market capitalization of $3.80 billion, a PE ratio of -16.73 and a beta of 1.03. The firm's 50-day moving average is $36.70 and its 200-day moving average is $33.36.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. The company had revenue of $109.98 million for the quarter, compared to analyst estimates of $125.66 million. Equities research analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.
Insider Buying and Selling at Zai Lab
In related news, Director William Lis sold 13,814 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $35.67, for a total value of $492,745.38. Following the transaction, the director directly owned 35,106 shares of the company's stock, valued at $1,252,231.02. This trade represents a 28.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Ying Du sold 7,072 shares of the stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $35.23, for a total transaction of $249,146.56. Following the sale, the chief executive officer owned 536,962 shares of the company's stock, valued at approximately $18,917,171.26. This represents a 1.30% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 110,155 shares of company stock valued at $3,531,035. Insiders own 4.96% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on ZLAB shares. Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the company an "outperform" rating in a research report on Monday, June 30th. Wall Street Zen lowered shares of Zai Lab from a "buy" rating to a "hold" rating in a report on Friday, June 27th. Finally, Citigroup restated a "buy" rating and set a $69.00 target price (up from $66.00) on shares of Zai Lab in a research report on Monday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Zai Lab has an average rating of "Moderate Buy" and a consensus price target of $57.22.
Read Our Latest Analysis on Zai Lab
Zai Lab Company Profile
(
Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
See Also
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
